NCT00326885 2018-10-17Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant AscitesNeovii BiotechPhase 2 Completed32 enrolled 12 charts
NCT00563836 2012-10-03Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian CancerNeovii BiotechPhase 2 Completed41 enrolled
NCT00377429 2012-07-19Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to ChemotherapyNeovii BiotechPhase 2 Completed47 enrolled 11 charts